MALCOLM BRENNER to Lymphokines
This is a "connection" page, showing publications MALCOLM BRENNER has written about Lymphokines.
Connection Strength
0.531
-
Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.
Score: 0.174
-
Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med. 1996 Oct; 2(10):1090-5.
Score: 0.135
-
Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother. 2007 Feb-Mar; 30(2):227-33.
Score: 0.069
-
Non-specific factor enhancement of human in vitro antigen-dependent antibody synthesis: role of B cell activation and T cell help. Immunology. 1984 Apr; 51(4):783-91.
Score: 0.057
-
Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003 Mar 01; 101(5):1718-26.
Score: 0.051
-
"The end of the beginning": molecular and cellular biology of gene therapy keystone. 14-20 January 1999. Biochim Biophys Acta. 1999 Jul 29; 1424(1):R5-9.
Score: 0.041
-
T cell depleted bone marrow transplantation in acute myeloblastic leukaemia: the way ahead. Bone Marrow Transplant. 1989 Jan; 4 Suppl 1:225-8.
Score: 0.005